Cloud Banner

Healthcare

Image

Global Anti-Nuclear Antibody Test Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Upcoming Report
  • Feb 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Anti-Nuclear Antibody Test Market, By Product (Reagents And Assay Kits, Systems, Software, And Services), Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren's Syndrome, Scleroderma, And Other Diseases), Technique (Enzyme-Linked Immunoassay, Immunofluorescence Assay, And Multiplex Assay), End Users (Hospitals, Clinical Laboratories, Physician Office Laboratories, And Others End Users) – Industry Trends and Forecast to 2030.

Antinuclear Antibody Test Market

Anti-Nuclear Antibody Test Market Analysis and Size

According to the American Autoimmune Related Disease Association (AARDA), about 50 million people suffer from autoimmune diseases in the U.S., and the incidence is growing yearly. In this regard, these antibody tests are widely used for diagnosis. Furthermore, the growing number of reagent rental agreements and increasing population and healthcare expenditure is also increasing the growth. Several latest research studies show that the immunofluorescence technique in the anti-nuclear antibody assay helps to diagnose diseases more accurately and thus, in a way, helps in market growth.

Data Bridge Market Research analyses the anti-nuclear antibody test market growth rate in the forecast period 2023-2030. The expected CAGR of anti-nuclear antibody test market tends to be around 13% in the mentioned forecast period. The market was valued at USD 1,700.75 million in 2022 and would grow to USD 4,521.35 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Anti-Nuclear Antibody Test Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product (Reagents And Assay Kits, Systems, Software, And Services), Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren's Syndrome, Scleroderma, And Other Diseases), Technique (Enzyme-Linked Immunoassay, Immunofluorescence Assay, And Multiplex Assay), End Users (Hospitals, Clinical Laboratories, Physician Office Laboratories, And Others End Users)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Erba Mannheim (Germany), Abbott (U.S.), Trinity Biotech (Ireland), Bio-Rad Laboratories, Inc. (U.S.). Thermo Fisher Scientific (U.S.), ZEUS Scientific, Inc. (U.S.),  Grifols, S.A (Spain). BioVision Inc (U.S.)., PerkinElmer, Inc. (U.S.)., F. Hoffmann-La Roche Ltd (Switzerland), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Zimmer Biomet, (U.S.)., Smith + Nephew (U.K.), Boston Scientific Corporation (U.S.), Organogenesis Inc. (U.S.) and Arthrex, Inc (Germany)

Market Opportunities

  • Growing R&D Activities For Anti-nuclear Antibody Assay
  • Increasing Demand for Reagents and Assay Kits For Assay

Market Definition

Anti-nuclear antibodies are the type of autoantibodies that bind to the cell's unique nucleus contents. Anti-nuclear antibody (ANA) means the fluorescent anti-nuclear antibody (FANA) and anti-nuclear antibody screen. The antibody test helps  to detect autoantibodies present in the human blood serum, and in this regard, indirect immunofluorescence and enzyme-linked immunosorbent assay tests are the most widely used tests that are performed.

Anti-Nuclear Antibody Test Market Dynamics

Drivers

  • Increasing Product Launches Associated with Disease Diagnostics

Several new diagnostic products for autoimmune diseases will boost the market growth during the study period. For instance, EUROIMMUN, a PerkinElmer, Inc. company, launched the EUROPattern Microscope Live (EPML) compact immunofluorescence microscope in 2021, enabling ultrafast automated immunofluorescence image acquisition. Also, indirect immunofluorescence tests (IIFT) are widely used to detect different antibodies in a patient sample. Thus, this factor will boost market growth.

  • Growing Investments by Major Market Players For Antibody Tests

Increasing investments to develop a diagnostic platform for autoimmune diseases such as rheumatoid arthritis and others are anticipated to boost market growth. For instance, Prantae Solutions is being funded under the India-Russia Joint Technology Assessment and Accelerated Commercialization Program in 2021 to develop a platform for rapid point-of-care diagnosis of Rheumatoid Arthritis (RA) by a technique known as multiplex immunofluorescence analysis based on disposable cartridges. Thus, this factor boosts market growth.

 Opportunities

  • Growing R&D Activities For Anti-nuclear Antibody Assay

Several new research studies using immunofluorescence in the anti-nuclear antibody assay help to diagnose different diseases more effectively, and it is anticipated to have a huge influence on the market. For instance, according to the study published by Arthritis Research & Therapy in 2022, systemic lupus erythematosus (SLE) patients' saliva was assayed for ANA using immunofluorescence (IF). It showed that salivary ANA IF intensities were considerably higher in these patients compared to healthy controls. Thus, growing R&D activities specifying the benefits of immunofluorescence tests will increase global demand, thus boosting the market growth.

  • Increasing Demand for Reagents and Assay Kits For Assay

The rising demand for reagents and assay kits boost the total performance of an assay, thus boosting the market's growth. They help create standardized workflows to help researchers in numerous fields. There are standard reagents that help achieve exact and efficient results. Improved efficiency, standardized results, and cost-effectiveness are anticipated to enhance market growth further.

Restraints/Challenges

  • Higher Diagnostic Errors Associated With Antibody Tests

An increasing rate of diagnostic errors may hamper the market growth. For instance, according to the American College of Rheumatology, healthy people with no health conditions or using medicines such as isoniazid and procainamide show false positive anti-nuclear antibody tests. This test lacks a great amount of specificity. Thus, this factor hampers the market growth.

This anti-nuclear antibody test market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anti-nuclear antibody test market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In 2022, THERADIAG made an agreement with Quotient Limited, a commercial-stage diagnostics company. The two companies will enter into partnership to boost autoimmune diagnostics by leveraging Quotient's MosaiQ platform.
  • In 2022, ZEUS Scientific received FDA clearance for the ZEUS dIFine IFA system for use with ZEUS' ANA HEp-2 indirect fluorescent antibody (IFA) assay. FDA clearance of HEp-2 ANA IFA test system on the dIFine system includes positive and negative determination and eight common ANA HEp-2 staining patterns.

Global Anti-Nuclear Antibody Test Market Scope

The anti-nuclear antibody test market is segmented on the basis of product, disease, technique and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product 

  • Reagents And Assay Kits
  • Systems
  • Software And Services

Disease

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Sjögren's Syndrome
  • Scleroderma
  • Other Diseases

Technique

  • Enzyme-Linked Immunoassay
  • Immunofluorescence Assay
  • Multiplex Assay

End-user

  • Hospitals
  • Clinical Laboratories
  • Physician Office Laboratories
  • Others End Users

Anti-Nuclear Antibody Test Market Regional Analysis/Insights

The anti-nuclear antibody test market is analyzed and market size insights and trends are provided by product, disease, technique and end users as referenced above.

The major countries covered in the anti-nuclear antibody test market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for the anti-nuclear antibody test market throughout the forecast period due to various unmet clinical needs and needs for better diagnosis. Unmet needs for autoimmune disease diagnostics in several countries, such as India, are anticipated to boost the regional demand during the forecast period.

North America dominates the market due to the most well-established markets concerning the adoption of ANA testing, healthcare infrastructure, patient awareness, and the increasing presence of advanced tests. Thus, these factors enhance the growth of the market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Anti-Nuclear Antibody Test Market Share Analysis

The anti-nuclear antibody test market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related anti-nuclear antibody test market.

Key players operating in the anti-nuclear antibody test market include:

  • Erba Mannheim (Germany)
  • Abbott (U.S.)
  • Trinity Biotech (Ireland)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Thermo Fisher Scientific (U.S.)
  • ZEUS Scientific, Inc. (U.S.),
  • Grifols, S.A (Spain)
  • BioVision Inc (U.S.)
  • PerkinElmer, Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • EUROIMMUN Medizinische Labordiagnostika AG (Germany)
  • Zimmer Biomet, (U.S.)
  • Smith + Nephew (U.K.)
  • Boston Scientific Corporation (U.S.)
  • Organogenesis Inc. (U.S.)
  • Arthrex, Inc (Germany)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The anti-nuclear antibody test market was USD 1700.75 million in 2022.
The anti-nuclear antibody test market is projected to grow at a CAGR of 13% during the forecast period of 2023-2030.
The Anti-Nuclear Antibody Test Market report is segmented by product, disease, technique, and end users.
North America dominates the market due to the most well-established markets concerning the adoption of ANA testing, healthcare infrastructure, patient awareness, and the increasing presence of advanced tests. Thus, these factors enhance the growth of the market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials